People with an inherited genetic disorder - xeroderma pigmentosum (XPV)which makes them very sensitive to sunlight, have an enzyme missing and this makes them more prone to get skin cancers.
The findings by researchers from Mount Sinai School of Medicine, paves way towards therapies that would help protect people with XPV from developing skin cancers.
Advertisement
The research team determined that, in the general population, DNA polymerase eta, an enzyme able to overcome the barriers created by sun damage and ultraviolet rays and continue replicating DNA strands, is structured differently from any other polymerase.
However, in people with XPV, since this enzyme is missing, they fail to bypass this damage, causing the replication process to stall, resulting in mutations and extremely high susceptibility to skin cancer.
![Ultra-Violet Radiation]( "Ultra-Violet Radiation")
Ultraviolet radiations are electromagnetic radiations with wavelengths shorter than the shortest wavelength of visible light, " the rays beyond the rainbow".
Researchers have never been able to fully determine a structural basis for why the enzyme can get around UV damage.
After nearly a decade of research, the researchers successfully developed a crystal model, or a three dimensional chemical derivation, of the enzyme.
They determined that in the general population, DNA polymerase eta suppresses skin cancer because the active site, where chemical reactions required to replicate DNA take place, can adjust much better to UV damage than any other DNA polymerase.
"We have been unable to study how DNA polymerase eta can replicate through UV damage because we did not have a crystal structure of the enzyme to study. Our team succeeded in developing this structure and determining what makes this enzyme unique," Nature quoted Dr. Aneel K. Aggarwal, Professor, Structural and Chemical Biology, Mount Sinai School of Medicine, as saying.
The researchers generated crystals and analyzed them using X-rays.
They determined that the active site of DNA polymerase eta is structured in such a way that it can easily accommodate the UV induced DNA lesions and replicate through them.
"Now that we know the structural basis for the suppression of skin cancers by this enzyme, one question for the future is if there's a way to restore its function in people with XPV and reduce their risk for cancer," said Aggarwal.
The study is published in the current issue of the journal Nature.
Source: ANI
Ultra-Violet Radiation
Ultraviolet radiations are electromagnetic radiations with wavelengths shorter than the shortest wavelength of visible light, " the rays beyond the rainbow".
Advertisement
Researchers have never been able to fully determine a structural basis for why the enzyme can get around UV damage.
After nearly a decade of research, the researchers successfully developed a crystal model, or a three dimensional chemical derivation, of the enzyme.
They determined that in the general population, DNA polymerase eta suppresses skin cancer because the active site, where chemical reactions required to replicate DNA take place, can adjust much better to UV damage than any other DNA polymerase.
"We have been unable to study how DNA polymerase eta can replicate through UV damage because we did not have a crystal structure of the enzyme to study. Our team succeeded in developing this structure and determining what makes this enzyme unique," Nature quoted Dr. Aneel K. Aggarwal, Professor, Structural and Chemical Biology, Mount Sinai School of Medicine, as saying.
The researchers generated crystals and analyzed them using X-rays.
They determined that the active site of DNA polymerase eta is structured in such a way that it can easily accommodate the UV induced DNA lesions and replicate through them.
"Now that we know the structural basis for the suppression of skin cancers by this enzyme, one question for the future is if there's a way to restore its function in people with XPV and reduce their risk for cancer," said Aggarwal.
The study is published in the current issue of the journal Nature.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.
Polymerases theta and delta assist in the development of new cancer drugs known as polymerase theta inhibitors, currently undergoing clinical trials.